Anika Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 11/30/25 | FY 12/31/24 | FY 12/31/23 | FY 11/30/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $112.8M | — | $119.9M | $120.8M | — |
| Cost of revenue | $49.0M | — | $43.9M | $38.3M | — |
| Gross profit | $63.8M | — | $76.0M | $82.5M | — |
| Selling, general & administrative | $49.1M | — | $55.6M | $59.9M | — |
| Research and development | $25.8M | — | $25.5M | $21.8M | — |
| Operating income | -$11.1M | — | -$5.1M | $844,000 | — |
| Pretax income | -$9.3M | — | -$2.8M | $3.2M | — |
| Income tax expense | $672,000 | — | $6.1M | $6.6M | — |
| Net income | -$10.9M | — | -$56.4M | -$82.7M | — |
| Balance Sheet | |||||
| Cash and equivalents | $57.5M | — | $55.6M | $68.7M | — |
| Current assets | $103.4M | — | $113.7M | $163.3M | — |
| Total assets | $190.3M | — | $202.7M | $270.6M | — |
| Current liabilities | $21.9M | — | $23.3M | $31.1M | — |
| Stockholders' equity | $143.5M | — | $154.0M | $212.3M | — |
| Cash Flow Statement | |||||
| Cash from operations | $11.2M | — | $5.4M | -$1.8M | — |
| Depreciation and amortization | $5.4M | — | $5.0M | $4.9M | — |
| Stock-based compensation | $10.1M | — | $13.1M | $15.2M | — |
| Capital expenditure | $6.8M | — | $7.7M | $5.4M | — |
| Free cash flow | $4.4M | — | -$2.3M | -$7.2M | — |
| Share repurchases | $9.5M | — | $10.9M | $5.0M | — |
| Impairments | $0 | $0 | $2.5M | $62.2M | $0 |
Shares outstanding 13.3M · Free float 76.0%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.